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Abstract
Objective: This study prospectively assessed putative promising biomarkers for
use in assessing infants with spinal muscular atrophy (SMA). Methods: This
prospective, multi-center natural history study targeted the enrollment of SMA
infants and healthy control infants less than 6 months of age. Recruitment
occurred at 14 centers within the NINDS National Network for Excellence in
Neuroscience Clinical Trials (NeuroNEXT) Network. Infant motor function
scales and putative electrophysiological, protein and molecular biomarkers were
assessed at baseline and subsequent visits. Results: Enrollment began November, 2012 and ended September, 2014 with 26 SMA infants and 27 healthy
infants enrolled. Baseline demographic characteristics of the SMA and control
infant cohorts aligned well. Motor function as assessed by the Test for Infant
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Motor Performance Items (TIMPSI) and the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) revealed significant differences between the SMA and control infants at baseline. Ulnar
compound muscle action potential amplitude (CMAP) in SMA infants
(1.4  2.2 mV) was significantly reduced compared to controls (5.5  2.0
mV). Electrical impedance myography (EIM) high-frequency reactance slope
(Ohms/MHz) was significantly higher in SMA infants than controls SMA
infants had lower survival motor neuron (SMN) mRNA levels in blood than
controls, and several serum protein analytes were altered between cohorts.
Interpretation: By the time infants were recruited and presented for the baseline visit, SMA infants had reduced motor function compared to controls.
Ulnar CMAP, EIM, blood SMN mRNA levels, and serum protein analytes were
able to distinguish between cohorts at the enrollment visit.

Introduction
Spinal muscular atrophy (SMA) is the leading genetic
cause of death in infants, exhibits a wide range of clinical
severity and has an incidence of one in 11,000 live
births.1,2 SMA is caused by homozygous deletion or
mutation in the SMN1 (survival motor neuron 1) gene
and retention of the nearly identical gene, SMN2 (survival
motor neuron 2), which results in reduced expression of
full-length SMN protein.3,4 In humans, SMN2 is present
in the same genomic region and differs from SMN1 by a
single-nucleotide substitution that results in the exclusion
of exon 7 in approximately 90% of SMN transcripts.5,6
The mRNA that results, SMND7, produces a truncated
protein that is nonfunctional and targeted for degradation.7,8
Clinically, SMA is characterized by skeletal muscle
weakness and, in a substantial majority of severely
affected individuals, respiratory insufficiency and premature death. Disease severity spans a wide range of phenotypes divided into five categories based upon maximal
motor function: type 0, (neonates who present with severe hypotonia often with history of decreased fetal movements), type 1 (never sit independently), type 2 (sit but
never stand independently), type 3 (ambulatory children),
and type 4 (ambulatory adults).9,10 SMN2 copy number
correlates inversely with clinical severity in humans and
motor function and survival in murine models.11–14 Thus,
SMN2 copy number is a prognostic biomarker that predicts future clinical outcome.
Clinical studies designed to increase the expression of
the SMN protein are underway in infants with SMA
(ClinicalTrials.gov: NCT02193074, NCT02292537, NCT02
386553, NCT02122952, NCT02462759, and NCT022
68552).15,16 Natural history studies in the SMA type 1
population demonstrated shortened lifespan, with 68%
mortality within the first 2 years of life.9,10 With the
advent of standardized care guidelines,17 the mortality of
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SMA type 1 infants has been reduced at 2 years of age to
30%, with nearly half of these infants dependent upon
noninvasive ventilation.18 In a recent observational study,
SMA infants who developed symptoms prior to 6 months
of age demonstrated very poor motor function and significant motor loss electrophysiologically at the enrollment
visit.19 Thus, there is heightened need to identify and validate physiological and molecular biomarkers in the SMA
type 1 population and to obtain longitudinal outcome
measures for use in future SMA infant clinical trials.
We sought to determine the feasibility and reliability of
testing specific putative physiological and molecular SMA
biomarkers in infants with SMA and in age-matched
healthy control infants. We performed a systematic, multi-center, longitudinal natural history study in SMA
infants designed to mimic a hypothetical phase 3 interventional clinical trial. Our goals were: 1) to determine
the natural history of motor function during the first 2
years of life in infants with SMA and in healthy infants,
2) to determine the natural history of putative electrophysiological and molecular biomarkers in infants with
SMA and healthy infants 3) to determine the relationship
between putative electrophysiological and molecular
biomarkers to motor function in infants with SMA and
healthy infants.

Subjects and Methods
This study was performed and supported by the National
Network for Excellence in Neuroscience Clinical Trials
(NeuroNEXT) Clinical Trial Network and originated from
The Ohio State University Wexner Medical Center. The
NeuroNEXT infrastructure consists of 25 clinical centers
geographically distributed across the United States, a Central Coordinating Center at Massachusetts General Hospital and a central Data Coordinating Center at University
of Iowa (Table S1). Fifteen sites (Table 1) began
enrollment in November 2012. Guardians of all subjects
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provided written, informed consent approved by the
NeuroNEXT central institutional review board20 at the
enrolling sites.

Study design
This was a prospective, longitudinal natural history study
of infants with genetically confirmed SMA and healthy
control infants. Enrollment was restricted to infants who
were 6 months of age or younger and were born between
36 and 42 weeks of gestation. The study was designed to
mimic the inclusion and timing of future SMA clinical
trials targeting treatment to SMA infants. Therefore, the
diagnosis of SMA was made by study investigators or
community neurologists and confirmed with clinical
genetic testing prior to enrollment. Asymptomatic subjects who had been genetically tested prior to the enrollment were permitted. Subjects were excluded if they
required noninvasive ventilatory support (i.e., BiPAP) for
more than 12 hours/day, had a comorbid illness or were
enrolled in an SMA therapeutic clinical trial. SMA infants
taking any therapies thought to increase SMN expression,
such as valproic acid, were excluded from the study. The
absence of an SMN1 gene deletion/mutation was confirmed for each healthy control infant.
The baseline study visit occurred prior to the age of
6 months and as young as possible, following either genetic
confirmation of SMA (with or without clinical symptoms
at time of enrollment) or identification as a suitable normal
control subject. Thereafter, study visits were scheduled to
occur according to age at 3 (if applicable), 6, 9, 12, 18, and
24 months. In this report, we present the baseline visit
Table 1. Baseline characteristics of SMA and healthy control infant
cohorts.

Demographics
Females
White race
Hispanic
Age at enrollment (months)
Baseline visit weight (lbs)
Gestational age (weeks)
Birth weight (lbs)
Birth length (inches)
SMN2 copy number
1
2
3
4
Unknown
SMN2 gene modifier c.859G>C

SMA (N = 26)

Control (N = 27)

N (%)
15 (58)
24 (92)
6 (23)
Mean (SD)
3.7 (1.7)
13.4 (2.2)
38.8 (1.5)
7.2 (1.2)
20.1 (1.2)
N (%)
0
16 (64)
5 (19)
1 (4)
4 (15)
0

N (%)
14 (52)
24 (89)
3 (11)
Mean (SD)
3.3 (2.0)
13.4 (3.3)
39.0 (1.4)
7.0 (1.4)
20.0 (1.0)
N (%)
12 (44)
13 (48)
1 (4)
0
1 (4)
0

results. Twenty-seven healthy infants were enrolled within
12 months; 26 infants with SMA were enrolled concurrently over 22 months. Confirmation of the SMN1 exon 7
deletion and SMN2 copy number were performed as previously described.21 In addition, DNA from SMA subjects
was screened for the SMN2 gene positive modifier mutation c.859G>C.22
The order of study procedures was strictly adhered to
at all fifteen enrolling sites to minimize site-to-site and
visit-to-visit variability. Subjects were asked to present to
the visit in morning, fully rested. Funds were available for
family travel and accommodations near the study site to
reduce the confounder of travel time and time of day.
After a medical history and a brief general examination,
infant motor function testing was performed, followed by
electrical impedance myography (EIM) testing, followed
by ulnar compound muscle action potential (CMAP) testing, followed by a single peripheral blood draw.

Motor function testing
Infant motor function was assessed by certified physical
therapists who were required to pass reliability training and
testing prior to enrollment. All subjects were evaluated
using the Test of Infant Motor Performance Screening Items
(TIMPSI), a 29-item, 99 point scale evaluation of infant
motor function that has been shown to be valid and reliable
in infants with SMA type 1.23 After testing, all subjects were
required to have a 20-minute rest period that could include
nursing/feeding. Subjects who scored less than 41 on the
TIMSPI were then evaluated using The Children’s Hospital
of Philadelphia Infant Test for Neuromuscular Disorders
(CHOP-INTEND) which is a validated 16-item, 64-point
scale shown to be reliable in SMA type 1 subjects.19,24 Subjects scoring 41 or greater on the TIMPSI were evaluated
using the Alberta Infant Motor Scale (AIMS), a 58-item
observational scale developed to assess motor development
in children from birth until independent walking.25,26

Compound muscle action potential (CMAP)
Ulnar CMAP measurements were obtained from the abductor digiti minimi (ADM) muscle by trained electromyographers using standardized electrode placement on the basis
of anatomical landmarks. The low-frequency and highfrequency filter settings were set to 10 Hz and 10 kHz,
respectively. Skin temperature was maintained at >33°C.
Two adhesive strip electrodes (Carefusion Disposable Ring
Electrode with Leads, order number 019-439300), trimmed
to the width of each subject’s ADM muscle, were used for
recording. The G1 recording electrode was placed on the
ADM muscle at 1/3 of the distance measured from the
pisiform bone to the fifth metacarpophalangeal joint with
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the length of the electrode-oriented orthogonal to the direction of the muscle fibers. The G2 reference electrode was
placed on the ulnar aspect of the fifth metacarpophalangeal
joint. An adhesive ground electrode (Carefusion Tab Electrodes 1.0 meter leads, order number 019-406600) was
placed on the dorsum of the hand. The ulnar nerve was
supramaximally stimulated either at the wrist or just proximal to the ulnar groove at the elbow using pediatric sized
bipolar probe. Square-wave stimulations of 0.2 msec duration and gradually increasing intensity were delivered to
reach 120% of the intensity required to elicit a maximal
CMAP response. Maximum values for negative peak (NP)
amplitude and NP area were recorded.

Electrical impedance myography (EIM)
Measurements were obtained following the motor function tests using a multi-frequency (1000 Hz–10 MHz)
impedance system (Skulpt Inc. EIM1103, San Francisco,
CA). As this study was the first time EIM had been performed in infants, a novel probe was designed specifically
for use in this population. Muscle groups were tested in a
specific order as follows: right biceps, right wrist extensors, right quadriceps, right tibialis anterior, left biceps,
left wrist extensors, left quadriceps, and left tibialis anterior muscles. Measurements were performed three times
on each muscle before moving on to the next and the
two closest sets of data averaged. All data were transferred
in a blinded fashion to a central database. Predetermined
EIM metrics based on data obtained in older healthy and
SMA-affected children27 were derived from the full set of
impedance data and transferred to the DCC for analysis.

Blood processing
A single peripheral blood draw was then obtained as the
last study procedure by an experienced pediatric phlebotomist. Given the challenge and small blood volume of
infants, a strict order of blood samples was adhered to:
2 cc blood into a PAXgene tube for SMN mRNA determination, 8 cc blood into a CPT tube for plasma, and PBMC
isolation followed by a 2 cc into a purple top for DNA
extraction. The CPT tube was processed at each site as previously described28 and PBMCs resuspended in freezing
medium consisting of 10% DMSO in FBS prior to shipment to the central processing laboratory (Kolb Lab).

SMN mRNA quantification
Total mRNA was isolated from the PAXgene tube as previously described.28 mRNA was converted to cDNA using
random hexamer primers and AMV-RT (7041Z, Affymetrix) according to the manufacture’s direction. SMN
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mRNA analysis was performed using Droplet Digital PCR
(ddPCR) (Bio-Rad Laboratories, Hercules, CA). The following primers were used for detection of full-length
SMN expression: hSMN_FL_Ex7_FP: 50 CAAAAAGAAGG
AAGGTGCTCA, hSMN_FL_Ex8_RP: 50 TCCAGATCT
GTCTGATCGTTTC, hSMN_FL_Ex7/8 probe: 50 FAM-TT
AAGGAGAAATGCTGGCATAGAGCAGCAC-MGB. SMN
expression was normalized to HPRT expression using the
PrimePCRTM ddPCRTM Expression Probe Assay for intronspanning
human
HPRT1
with
HEX
assay
(dHsaCPE5192872, Bio-Rad). Mulitplex reactions were
performed with 2–5 lL of cDNA as required to obtain a
sufficient number of positive droplets. Template, primers
(900 nM final), probes (250 nM final), and 2 9 ddPCR
Supermix in 20 lL final volume were converted into droplets with the QX200 droplet generator (Bio-Rad Laboratories) and PCR was run on a classic MJ thermal cycler
under standard conditions: 95°C for 10 minutes followed
by 40 cycles of 94°C for 30 seconds, 60°C for 1 minute,
and a final step of 98°C for 10 minutes. After PCR, droplet counts were measured on the QX200 droplet digital
reader (Bio-Rad Laboratories). Concentration of sample
was determined by fitting droplet counts to the Poisson
distribution using QuantaSoft software (Bio-Rad Laboratories). SMN mRNA expression per sample was normalized by dividing the SMN concentration by the HPRT
concentration and plotted as Relative Fluorescent Units
(RFU).

SMN protein levels
For the SMN protein measurements, peripheral blood
was drawn into a cell preparation tube and peripheral
blood mononuclear cells (PBMCs) were isolated as previously described.29 PBMCs were cryopreserved at each
study site and then shipped to the central laboratory
(Kolb Lab) where they were stored at 80°C. Once all
baseline samples were collected, SMN protein was
measured at PharmOptima (Portage, MI) using the company’s proprietary electrochemiluminescence immunoassay based on the Meso Scale Discovery technology. The
assay is a quantitative sandwich immunoassay, where a
mouse monoclonal antibody (2B130) functions as the capture antibody and a rabbit polyclonal anti-SMN antibody
(Protein Tech, Cat. No. 11708-1-AP) labeled with a
SULFO-TAGTM is used for detection. SMN levels are
determined from a standard curve using recombinant
SMN protein (Enzo Life Sciences, Cat. No. ADI-NBP201-050). The dynamic range of the assay is 10 pg/mL to
10,000 pg/mL. PBMC samples were received by PharmOptima, frozen and were maintained at 80°C until
thawed for enumeration. Samples were thawed quickly in
a 37°C water bath in batches of eight samples per thawing
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and enumeration event in order to avoid prolonged incubation prior to cell lysis. Samples were diluted 10-fold
into PBS prior to enumeration via direct hemocytometric
counting. Finally, cells were lysed at a density of 1 X 107
cells/mL. Lysates were maintained at 80°C until the
time of assay.

SMA-MAP quantification
Plasma samples were isolated for the CPT tubes, frozen
immediately and stored at 80°C in cryovials. Frozen
samples were sent to a central processing laboratory at
Myriad and processed to quantify 25 plasma protein analytes that have been identified as putative serum SMA
biomarkers.31,32 All samples were stored at 80°C until
tested. The samples were thawed at room temperature,
vortexed, spun at 4000 RPM for 5 minutes for clarification and volume was removed for MAP analysis into a
master microtiter plate. Using automated pipetting, an
aliquot of each sample was introduced into one of the
capture microsphere multiplexes of the Multi Analyte
Profile. The mixture of sample and capture microspheres
were thoroughly mixed and incubated at room temperature for 1 hour. Multiplexed cocktails of biotinylated,
reporter antibodies for each multiplex were then added
robotically and after thorough mixing, were incubated for
an additional hour at room temperature. Multiplexes
were developed using an excess of streptavidin-phycoerythrin solution that was thoroughly mixed into each multiplex and incubated for 1 hour at room temperature. The
volume of each multiplexed reaction was reduced by vacuum filtration and the volume increased by dilution into
matrix buffer for analysis. Analysis was performed in a
Luminex 100 instrument and the resulting data stream
was interpreted using proprietary data analysis software
developed at Rules-Based Medicine. For each multiplex,
both calibrators and controls were included on each
microtiter plate. Eight-point calibrators were run in the
first and last column of each plate and 3-level controls
were included in duplicate. Testing results were determined first for the high-, medium-, and low controls for
each multiplex to ensure proper assay performance.
Unknown values for each of the analytes localized in a
specific multiplex were determined using 4 and 5 parameter, weighted- and nonweighted-curve fitting algorithms
included in the data analysis package.

Statistical analysis
Continuous variables were summarized by means, standard deviation, minimum, and maximum values. Categorical variables were summarized by percentages.
Comparisons of continuous variables between the SMA

SMA Infant Biomarker Study

and healthy control cohorts were performed using two
sample t-tests. Comparisons of categorical variables
between the two cohorts were performed using chi-square
tests. All statistical tests were two-sided and used a significance level of 0.05. No adjustments for multiple comparisons were made.
Pearson’s correlation coefficients between subject’s age
at enrollment and all continuous outcomes were
estimated separately for each cohort. Similarly, the correlations between motor function tests (TIMPSI and
CHOP-INTEND) and biomarkers (CMAP, EIM, SMN
mRNA, and SMA-MAP) were estimated separately for
each cohort. Additional analyses restricted to the subgroup of SMA subjects with two copies of the SMN2 gene
were also performed. All analyses were performed using
SAS version 9.3 or later.

Results
Baseline demographics
The first site was activated and enrollment began in
November 2012. All fifteen sites had passed certification
for MFTs and CMAP and were activated by February
2013. Enrollment of 27 healthy infants was completed in
October 2013 and enrollment of 26 SMA infants was
completed in September 2014. The baseline visit was
defined as the enrollment visit. Every infant was less than
6 months of age at the initial visit. The SMA and healthy
infant cohorts aligned well on baseline demographic characteristics (Table 1). The average age of enrollment for
the SMA and healthy cohorts was 3.7 months (SD = 1.7)
and 3.3 months (SD = 2.0), respectively; 57.7% of the
SMA infants and 51.9% of the healthy infants were
female. Birth weight and height were nearly identical in
the two cohorts. In the SMA cohort, 15 infants were
found to have two copies of SMN2 gene, five had three
copies and a single infant had four copies. SMN2 copy
number was not determined in five SMA infants because
of a failure to obtain sufficient blood sample for DNA
testing on the baseline or subsequent visits. No infants in
the SMA cohort for whom DNA was tested had the
SMN2 c.859G>C mutation. In the healthy cohort, we
confirmed that no infant had a homozygous deletion or
mutation in the SMN1 gene. There were four healthy
control infants who were carriers with one copy of SMN1
gene and all of these infants had siblings with the diagnosis of SMA. Three control infants had three copies of the
SMN1 gene.
The month of onset of symptoms was obtained from
the parent or guardian during the baseline visit (Table 2).
The majority of SMA infants (9) had symptom onset in
the second month of life. There were six infants with
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Table 2. Age of symptom onset for SMA subjects.

SMA
SMA, SMN2 = 2

< 1 month

1–2 months

2–3 months

4–5 months

Not recorded

Total

6
6

9
5

4
3

1
1

6
1

26
16

symptom onset prior to 1 month of age and all of these
infants had two copies of SMN2. All but one SMA infant
for whom this data were collected had symptom onset
prior to the 3 months of age. This data was not recorded
in six SMA infants. When asked if the infants had feeding
or swallowing problems at the time of the baseline visit,
ten (38.5%) of parents or guardians responded, yes.

period. Consequently, only three SMA infants and 13
control infants were assessed using the AIMS. No SMA
infants with two copies of SMN2 received the AIMS. The
average AIMS score for the SMA cohort (8.7, SD = 3.5)
was lower than the control cohort (13.8, SD = 4.5). There
was a positive correlation between AIMS scores and age
in the control cohort (r = 0.650, n = 13, P = 0.02).

Motor function

Baseline putative physiologic biomarkers

All motor function values are plotted against age at time
of assessment in Figure 1. Motor function was measured
using the TIMPSI for all infants. The average TIMPSI
score for the SMA cohort, 34.9 (SD = 20.9, n = 26,
range = 14–94), was significantly lower than in the
healthy cohort, 66.1 (SD = 22.6, n = 27, range = 15–96,
P < 0.01). SMA infants with two SMN2 copies had an
average TIMPSI score of 27.2 (SD = 8.0, n = 16,
range = 15–49), and there was no correlation with age
(Table S2). Moreover, at enrollment no SMA infant with
two copies of SMN2 had a TIMPSI greater than 51. In
the healthy control cohort, TIMPSI score had a positive
correlation with age (r = 0.80, P < 0.0001). There was no
difference noted in control infants with one, two, or three
copies of the SMN1 gene. All healthy control infants older
than 10 weeks of age had TIMPSI scores above 51.
The CHOP-INTEND was utilized to measure motor
function in infants scoring less than 41 on the TIMPSI
after the TIMSPI and a mandatory 20-minute rest period.
As a result, a total of 23 SMA infants and 14 control
infants were assessed using the CHOP-INTEND. All 16
SMA infants with two copies of SMN2 were assessed using
the CHOP-INTEND. The average CHOP-INTEND score
for the SMA cohort, 21.4 (SD = 9.6, n = 23, range = 10–
52) was significantly lower than the control cohort, 50.1
(SD = 10.2, n = 14, ranged 32–62, P < 0.01). The average
CHOP-INTEND score for SMA infants with two copies of
SMN2 was 20.2 (SD = 7.4, n = 16, range = 10–33) and
the maximum score in this subgroup was 33. There was no
correlation between CHOP-INTEND scores and age in the
SMA or control cohorts. There was excellent correlation
between the CHOP-INTEND and TIMPSI scores for SMA
(r = 0.866, n = 22, P < 0.0001) and control cohorts
(r = 0.839, n = 9, P = 0.005).
The AIMS was assessed in infants scoring 41 or higher
on the TIMPSI following the mandatory 20-minute rest

Ulnar CMAP recordings were well tolerated. However,
the CMAP for one SMA infant was not obtained. The
peak amplitude (mV) for each subject is plotted against
age at assessment in Figure 2. The average CMAP peak
amplitude for the SMA cohort, 1.4 mV (SD = 2.2,
n = 25) was significantly lower than the control cohort,
5.5 mV (SD = 2.0, n = 27, P < 0.01). The average CMAP
peak amplitude for SMA infants with two copies of
SMN2 was 0.5 mV (SD = 1.0, n = 15). The CMAP values
obtained in the control infants did not correlate with the
motor function ability as measured by the TIMPSI
(r = 0.006, n = 27, P = 0.9773) and the CHOP-INTEND
(r = 0.4105, n = 14, P = 0.2725). The CMAP values
obtained in the SMA infants had a positive correlation
with motor function ability as measured by the TIMPSI
(r = 0.785, n = 25, P < 0.0001) and the CHOP-INTEND
(r = 0.556, n = 21, P = 0.0088). Interestingly, in the subgroup of SMA infants with two copies of SMN2 there is
no correlation with TIMPSI (r = 0.276, n = 15,
P = 0.320) or CHOP-INTEND (r = 0.283, n = 15,
P = 306). The results for the ulnar CMAP area were also
analyzed and comparisons between groups and correlations were consistent with the results for ulnar CMAP
amplitude.
Electrical impedance measurements were well tolerated.
The test was not performed in two control infants at
baseline. Predetermined EIM outcomes were analyzed
based upon prior studies using EIM in older children
with SMA.27 Baseline EIM outcomes are presented in
Table 3. EIM outcomes were analyzed using 1) the average value of all muscles tested, 2) the average value of the
proximal muscles tested (right and left biceps and quadriceps), or 3) the average value of the distal muscles tested
(right and left wrist extensors and tibialis anterior muscles). Of the outcomes measured, high-frequency reactance slope (units) distinguished between SMA and
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A.

TIMPSI
TIMPSI < 41

TIMPSI = or > 41
Rest /
Comfort

20 min
CHOPINTEND

SMA

Control

AIMS

CHOP-INTEND

TIMPSI

B.

AIMS

Figure 1. Motor function assessments in SMA and healthy infants in the first 6 months of life. (A) Motor function testing paradigm. All infants
were tested using the TIMPSI. After the TIMPSI, a mandatory rest period of 20 minutes was followed by either the CHOP-INTEND or AIMS
assessment. Infants who scored less than 41 on the TIMPSI were tested using the CHOP-INTEND, otherwise the infant was tested using the AIMS
test. (B) Results of infant motor function tests for all infants as a function of the age at the time of enrollment visit. For the SMA cohort, the
SMN2 copy number for each infant is indicated by the color as indicated in the key by each graph. For the healthy cohort the SMN1 copy
number for each infant is indicated by the color as indicated in the key by each graph.
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Control

SMA

Figure 2. Ulnar compound muscle action potential is significantly reduced in SMA infants compared to healthy infants. Ulnar CMAP peak
amplitude (mV) in SMA and healthy control infants as a function of the age at the time of enrollment visit. For the SMA cohort, the SMN2 copy
number for each infant is indicated by the color as indicated in the key by each graph. For the healthy cohort, the SMN1 copy number for each
infant is indicated by the color as indicated in the key by each graph.

Table 3. Baseline electrical impedance myography results in SMA and healthy control infants.

All muscles grouped
50k Phase (SD)
50k Resistance (SD)
50k Reactance (SD)
HF phase slope (SD)
HF reactance slope (SD)
LF reactance slope (SD)
Distal muscles grouped
50k Phase (SD)
50k Resistance (SD)
50k Reactance (SD)
HF phase slope (SD)
HF reactance slope (SD)
LF reactance slope (SD)
Proximal muscles grouped
50k Phase (SD)
50k Resistance (SD)
50k Reactance (SD)
HF phase slope (SD)
HF reactance slope (SD)
LF reactance slope (SD)

SMA N = 26

SMA: 2 SMN2
copy subgroup (N = 16)

Control N = 25

P value
SMA vs Control

P value
SMN2 = 2 vs Control

5.62
104.8
16.48
13.76
12.65
96.1

(2.54)
(21.09)
(27.83)
(7.87)
(4.39)
(2501)

5.39
108.0
10.81
15.53
12.53
426.1

(1.67)
(23.83)
(4.91)
(2.96)
(4.50)
(170.4)

6.21
99.11
10.90
13.33
7.99
336.2

(1.64)
(21.13)
(3.72)
(3.90)
(3.82)
(113.2)

0.3317
0.3367
0.3204
0.8073
0.0002
0.3870

0.1314
0.2190
0.9493
0.0616
0.0013
0.0487

5.04
100.9
17.23
15.16
14.10
181

(2.35)
(19.93)
(40.54)
(5.95)
(4.75)
(2963)

4.84
103.9
9.35
16.32
14.03
426.6

(1.69)
(21.95)
(4.17)
(2.80)
(5.16)
(253.4)

5.7
98.84
9.58
13.12
9.04
317.2

(1.89)
(33.77)
(3.59)
(6.11)
(4.22)
(171.9)

0.2724
0.7926
0.3457
0.2315
0.0002
0.4006

0.1452
0.5961
0.8636
0.0292
0.0017
0.1069

6.19
109.0
13.20
12.35
11.14
78.95

(2.96)
(23.18)
(7.86)
(10.18)
(4.86)
(1591)

5.94
112.0
12.25
14.75
11.00
425.7

(1.78)
(26.90)
(5.81)
(3.50)
(4.79)
(162.4)

6.72
99.33
12.21
13.54
6.70
354.7

(1.62)
(19.80)
(4.01)
(3.55)
(4.37)
(131.5)

0.4309
0.1151
0.5725
0.5767
0.0016
0.3869

0.1580
0.0895
0.9805
0.2941
0.0065
0.1317

Bold rows highlight outcomes where P value is equal to or less than 0.05.

control cohorts regardless of how the muscles were
grouped for analysis (Table 3).
Correlations of EIM outcomes from all muscles
grouped with age, TIMPSI and CHOP-INTEND are

8

tabulated in Table S2. In the control cohort, EIM outcomes 50k Phase, Resistance and Reactance and high-frequency reactance slope had a positive correlation with age
(Table S2). Similarly, in the control cohort there were
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many correlations between the TIMPSI motor function
score and EIM outcomes. TIMPSI scores in the control
infants had positive correlations with 50 kHz Phase
(r = 0.4968, n = 25, P = 0.0115), Resistance (r = 0.4769,
n = 25, P = 0.0159) and Reactance (r = 0.6506, n = 25,
P = 0.0004). TIMPSI scores in the control infants had
negative correlations with high-frequency reactance slope
(r = 0.4892, n = 25, P = 0.0131). Interestingly, there
was no correlation between EIM outcomes and CHOPINTEND scores in control infants.
In the SMA cohort, there was a strong positive correlation between 50k Resistance and age (r = 0.7649, n = 26,
P < 0.0001). This correlation also was seen in the subgroup of SMA infants with two copies of SMN2
(r = 0.7484, n = 16, P = 0.0009). There were no correlations between TIMPSI or CHOP-INTEND and any of the
EIM outcomes studied for the SMA cohorts (Table S2).

Baseline putative molecular biomarkers
Peripheral blood draws were tolerated although in some
cases an insufficient amount of blood was drawn for all
analyses. The SMN mRNA level, expressed as the ratio of
SMN to HPRT transcripts, for each subject is plotted
against age at assessment in Figure 3A. The average, baseline SMN/HPRT ratio in the SMA cohort, was 0.50
(SD = 0.14, n = 19) and was significantly lower than the
SMN/HPRT ratio of control cohort, 1.27 (SD = 0.44,
n = 19, P < 0.0001). The average SMN/HPRT ratio for
SMA infants with two copies of SMN2 was 0.47
(SD = 0.13, n = 12) and was also significantly lower than
the control cohort (P < 0.0001). There was no correlation
in either cohort between age and SMN mRNA level
(Table S2). In the control cohort, there was no correlation
between the TIMPSI score and SMN mRNA levels
(r = 0.244, n = 19, P = 0.315). In the subgroup of control
infants who were assessed using the CHOP-INTEND (these
infants scored < 41 on the TIMPSI), there was a positive
correlation between CHOP-INTEND score and SMN
mRNA level (r = 0.856, n = 7, P = 0.014). In the SMA
cohort, there were no correlations between the TIMPSI or
CHOP-INTEND with SMN mRNA levels (Table S2)
The SMN protein levels were measured from PBMC
samples. During the PBMC enumeration process involving direct microscopic examination, many samples were
found to have significant numbers of platelets in the samples, in two samples platelets were found to be in a
numerical excess of 10-fold to the PBMCs. Therefore, an
additional low-speed (200 x g) centrifugation step was
added resulting in a more purified PBMC sample. In
three baseline PBMC samples, there were too few cells to
count. The yield of the remaining samples ranged from 1
x 105 to 3 x 107 PBMCs. The SMN protein level for each

SMA Infant Biomarker Study

subject is plotted against age of assessment in Figure 3B.
The average, baseline SMN protein level in the SMA
cohort (6601.7 pg/107 PBMCs, SD = 3592.8, n = 18) and
was not significantly lower than the baseline SMN protein
level of control cohort (8967.8 pg/107 PBMCs,
SD = 5441.3, n = 21, P = 0.1212). In contrast, the average baseline SMN protein level for SMA infants with two
copies of SMN2 (5367.4 pg/107 PBMCs, SD = 3603.5,
n = 12) was lower than the control cohort (P = 0.0484).
There was no correlation in the control cohort between
age and SMN protein level (Table S2). However, there
was a negative correlation between age and SMN protein
levels in the SMA cohort (r = 0.632, n = 18,
P = 0.0049). In the control cohort, there was no correlation between the TIMPSI score and SMN protein level
(r = 0.101, n = 21, P = 0.664) or between the CHOPINTEND and SMN protein level (r = 0.245, n = 8,
P = 0.559). In the SMA cohort, there were also no correlations between the TIMPSI or CHOP-INTEND with
SMN protein levels (Table S2).
The concentration of 25 plasma protein analytes were
determined from 18 SMA infants and 20 control infants
at the baseline visit. The average baseline plasma analyte
concentrations are tabulated in Table 4. When compared
to the control cohort, the SMA cohort had lower concentrations of cadherin-13 (P = 0.0277), cartilage oligomeric
matrix protein (P = 0.0011), Insulin-like growth factor
binding protein 6 (P = 0.0135), peptidase D (P = 0.0236)
and tetranectin (P = 0.0493). When compared to the control cohort, the SMA cohort had higher concentrations of
myoglobin (P = 0.0220) and YKL-40 (0.0288). Comparisons between the control group and the SMA infants
with two copies of SMN2 improved the significance of
the differences between groups for all analytes except for
myoglobin (Table 4). In addition, significant differences
were found between the control group and the subgroup
of SMA infants with two copies of SMN2 for complement
component C1q receptor (P = 0.0227) and dipeptidyl
peptidase IV (P = 0.0260).
There were nine analytes that had a negative correlation with age at enrollment in the control cohort and ten
analytes that had a negative correlation with age at enrollment in the SMA cohort (Table S2). Only six analytes
(AXL receptor tyrosine kinase, cartilage oligomeric matrix
protein, complement component C1q receptor, Fibulin1C, Tenascin-X, and Thrombospondin-4) showed this
correlation in both the control and SMA cohorts. Interestingly, there were no analytes that demonstrated a positive correlation with age at enrollment in either cohort.
In the control infant cohort, there were negative correlations between the TIMPSI motor function score and the
plasma concentrations of complement component C1q
receptor (r = 0.681, n = 20, P = 0.0010), osteopontin
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A.
SMA

Control

B.
SMA

Control

Figure 3. Peripheral blood SMN mRNA and protein levels in SMA and healthy control infants. (A) Full-length SMN mRNA levels from whole blood
measured using ddPCR expressed as a ratio of SMN to HPRT. (B) SMN protein levels detected in PBMCs measured by SMN-ECL ELISA expressed
as pg/107 cells. For the SMA cohort, the SMN2 copy number for each infant is indicated by the color as indicated in the key by each graph. For
the healthy cohort, the SMN1 copy number for each infant is indicated by the color as indicated in the key by each graph.

(r = 0.528, n = 20, P = 0.0168) and thrombospondin-4
(r = 0.521, n = 20, P = 0.0187). In the SMA cohort,
there were positive correlations between the TIMPSI
motor function score and the plasma concentrations of
AXL Receptor Tyrosine Kinase (r = 0.586, n = 18,
P = 0.0107), cartilage oligomeric matrix protein
(r = 0.834, n = 18, P < 0.0001), dipeptidyl peptidase IV
(r = 0.603, n = 18, P = 0.0081), endoglin (r = 0.535,
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n = 18,
P = 0.0223),
HER2
(r = 0.544,
n = 18,
P = 0.0196), Insulin-like growth factor-binding protein 6
(0.580, n = 18, 0.0117), PEPD (r = 0.6037, n = 18,
P = 0.0080),
thrombospondin-4
(r = 0.615,
n = 18, P = 0.0066), and tetranectin (r = 0.669, n = 18,
P = 0.0024). The only analyte that correlated with both
the TIMPSI and the CHOP-INTEND score in the SMA
cohort was cartilage oligomeric matrix protein (Table S2).
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Table 4. SMA-MAP levels from blood samples in SMA and healthy control infants.

Analyte

SMA (N = 18)

SMA: 2 SMN2
copy subgroup
(N = 13)

Control (N = 20)

P value
SMA vs
Control

P value
SMN2 = 2
vs Control

Apolipoprotein B (Apo B) (lg/mL)
AXL receptor tyrosine kinase (AXL) (ng/mL)
C-Reactive protein (CRP) (lg/mL)
Cadherin-13 (T-cad) (ng/mL)
Cartilage oligomeric matrix protein (COMP) (ng/mL)
Cathepsin D (ng/mL)
Complement component C1q receptor (C1qR1) (lg/mL)
Complement factor H-related protein 1 (CFHR1) (lg/mL)
Dipeptidyl peptidase IV (DPPIV) (ng/mL)
Endoglin (ng/mL)
Fetuin-A (lg/mL)
Fibulin-1C (Fib-1C) (lg/mL)
Human epidermal growth factor receptor 2 (HER-2) (ng/mL)
Insulin-like growth factor binding
protein 6 (IGFBP6) (ng/mL)
Leptin (ng/mL)
Monocyte chemotactic protein 1 (MCP-1) (pg/mL)
Myoglobin (ng/mL)
Osteopontin (ng/mL)
Peptidase D (PEPD) (lg/mL)
Placenta growth factor (PLGF) (pg/mL)
Serum amyloid P-component (SAP) (lg/mL)
Tenascin-X (TN-X) (ng/mL)
Tetranectin (lg/mL)
Thrombospondin-4 (TSP4) (lg/mL)
YKL-40 (ng/mL)

842.3
20.17
1.94
6.83
388.4
412.3
14.62
1005
232.4
3.31
648.4
20.67
0.69
116.3

(310.3)
(6.57)
(6.28)
(3.18)
(221.2)
(243.5)
(8.54)
(675.4)
(86.12)
(0.87)
(187.2)
(4.95)
(0.23)
(48.25)

871.5
18.62
0.58
6.67
298.1
358.2
12.24
1000
215.1
3.08
653.2
20.00
0.63
106.2

(313.2)
(5.87)
(0.66)
(3.25)
(121.0)
(233.1)
(6.78)
(738.2)
(55.69)
(0.85)
(163.7)
(5.58)
(0.18)
(44.21)

645.2
23.37
0.48
9.72
617.5
486.8
20.64
942.9
282.1
3.32
622.0
19.65
0.76
153.9

(369.0)
(7.59)
(1.06)
(4.39)
(177.7)
(494.8)
(13.17)
(566.0)
(92.72)
(0.81)
(141.5)
(5.62)
(0.29
(40.92)

0.0850
0.1752
0.3423
0.0277
0.0011
0.5549
0.1075
0.7588
0.0969
0.9741
0.6241
0.5596
0.4375
0.0135

0.0779
0.0650
0.7623
0.0399
<0.0001
0.3242
0.0227
0.8031
0.0260
0.4143
0.5638
0.8620
0.1571
0.0034

3.46
255.4
32.71
151.0
9.39
19.00
3.53
184.8
7.39
22.51
10.11

(2.59)
(79.99)
(30.17)
(63.92)
(2.34)
(2.85)
(1.69)
(144.5)
(1.62)
(11.55)
(3.96)

3.39
252.2
30.56
136.8
8.84
18.54
3.70
151.5
6.78
18.86
10.45

(2.72)
(78.17)
(28.09)
(67.08)
(1.79)
(1.85
(1.84)
(114.1)
(1.23)
(9.21)
(3.90)

2.58
336.7
14.46
168.4
11.15
20.10
3.01
351.0
9.06
28.66
7.58

(1.65)
(160.2)
(7.78)
(46.75)
(2.24)
(5.04)
(1.72)
(464.9)
(3.20)
(21.95)
(2.85)

0.2177
0.0541
0.0220
0.3426
0.0236
0.4080
0.3564
0.1424
0.0493
0.2821
0.0288

0.3476
0.0529
0.0645
0.1204
0.0038
0.2183
0.2823
0.0798
0.0078
0.0876
0.0204

Bold rows highlight analytes where P value is equal to or less than 0.05.

C-reactive protein plasma concentration correlated with
the CHOP-INTEND (0.776, n = 15, 0.0007) but not the
TIMPSI (r = 0.288, n = 18, P = 0.2457) in SMA infants.

Discussion
We were successful in our efforts to recruit SMA and
healthy control infants into the study using 14 clinical
sites geographically distributed across the US. Our ability
to enroll in this challenging and vulnerable population
illustrates the utility and power of the clinical trial infrastructure that the NeuroNEXT Network was designed to
provide. Importantly, while some sites within the network
had extensive experience in the SMA infant population,
many sites did not. Thus, our data set may provide natural history data which are most relatable to large, multicenter SMA clinical trials involving sites with a heterogeneous experience level in infant SMA. Caution must be
made when using this data as a “historical control” in
future and current SMA infant clinical trials. The motivation of parents who enter their infant into an interventional trial compared to those who elect not to

participate may bias the standard of care, the use of
aggressive support and the timing of the initiation of hospice care.
By the time infants presented for the enrollment visit,
SMA infants have reduced motor function compared to
controls as reflected in both TIMPSI and CHOP-INTEND
enrollment scores for the SMA cohort. This finding, while
not surprising, is remarkably consistent with prior studies.19,33 This consistency, obtained in a multicenter format
similar to what would be expected in a large clinical trial
context, is an important replication and validation of earlier single center studies (Finkel, Krosschell, and Swoboda,
unpublished data). In addition, both the SMA cohort and
control cohort data provide an informed baseline expectation for motor function in Type I infants and may eventually help to inform what should be considered a
clinically important difference in the two motor function
tests following an intervention.
Ulnar CMAP and EIM assessed using multiple sites
bilaterally were both able to distinguish between cohorts
at the enrollment visit. The CMAP results in the SMA
infants closely match those seen in previous studies.33,34 It
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will be important to see how these already low values
change as these infants age. The extent of the loss of
CMAP response at the enrollment visit may not indicate
that motor unit function is irreversibly lost at the baseline
visit; however, it is clear that urgency is required to
recruit infants into trials prior to significant CMAP loss,
if feasible, to ensure the best possible outcomes. For the
subgroup of SMA infants with two copies of SMN2, the
CMAP values do not correlate with motor function,
whereas when the more mildly affected infants with three
or more copies of SMN2 are included in the analysis,
CMAP does correlate with motor function. This lack of
correlation with motor function in the SMA infants with
two copies of SMN2 may be the result of a sampling
error as the ulnar CMAP does not reflect the functional
status of motor units involved in proximal muscle function. This study also demonstrates that, for healthy
infants, CMAP responses appear stable from birth to
6 months of age, although a full analysis of the longitudinal responses in individual infants will provide more
definitive evidence. An analysis of the normal development of CMAP responses for each infant at the end of
the longitudinal study will provide important baseline
data for future clinical trials.
Of all the predetermined EIM measures studied, only
the high-frequency reactance slope distinguished SMA
from healthy children; many of the standard measures
that have shown differences in older children27,35 did not
do so in this group of infants. Moreover, EIM measures
only correlated with motor function in the healthy children. Two factors may have impacted these results. First,
there was no assessment of data quality. Unlike CMAP,
with which the investigators were quite familiar, the
impedance data were obtained virtually blindly; thus,
poor-quality data (e.g. due to electrode contact problems)
may have been included in this analysis. Second, following the design of the study, it has since become clear that
very young individuals have different impedance spectral
characteristics (including, e.g., peak reactance values far
above the standard 50 kHz frequency) (Rutkove, unpublished observations). Thus, the predetermined metrics
utilized in this study were likely not ideal for children of
this age. Further analysis of the raw data will be necessary to identify optimized parameters for infants that
can then be applied to the forthcoming longitudinal data
analysis.
SMN mRNA levels were lower in SMA infants as
expected, and there was no correlation between age and
SMN levels in SMA or control cohorts. Surprisingly, there
was a positive correlation detected in control infants
between SMN mRNA levels and the scores on the CHOPINTEND. It is worth noting, however, that only seven
control infants had both the CHOP-INTEND and a blood
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draw for SMN mRNA levels. There was no correlation
between SMN mRNA levels and the TIMPSI scores in 19
control infants. SMN protein levels were more variable
than the SMN mRNA levels. There were no correlations
between SMN mRNA levels and SMN protein levels as
measured from PBMCs in either cohort (r = 0.0184,
n = 31, P = 0.9217). We found variability in PBMC yield
from patient samples and were not able to process some
samples because of insufficient material. Since the start of
this project, it is now clear that measurement of SMN
protein levels from PBMC samples collected using the
CPT tubes is not optimal and a whole blood methodology is now available.36,37 The protocol was modified for
subsequent longitudinal visits to include collection of
whole blood so that future analysis of SMN protein in
this study may be improved.
There were many serum protein analytes that distinguished between SMA and control cohorts. Most of these
were in lower concentrations in the SMA infants compared
to the control infants with the exception of myoglobin and
YKL-40 that were found in higher concentrations in SMA
infant serum compared to controls. While it is difficult to
generalize the results of these disparate proteins, one general observation is that in the control cohort, if a protein
analyte concentration correlated with age, then it was a
negative correlation; the serum concentration of many of
the analytes decreased with increasing age of enrollment.
This overall trend was also seen in the SMA cohort with
two exceptions (Apolipoprotein B and Serum Amyloid PComponent) suggesting that the natural history of most
serum analytes studied here is to have reduced concentration with increasing age. Determination of the trends in
individual infants with increasing age will help to clarify
this possibility.
Future analysis of the longitudinal data sets from the
SMA infant and healthy infant control cohorts described
here will contribute to an understanding of the natural
history of SMA infants and provide important control
data for SMA infant interventional studies. It is clear
from our initial data, that infants with SMA presenting
prior to 6 months of age can be enrolled into studies
readily. However, given the poor motor function and
electrophysiological outcomes at enrollment, efforts
should be made to enroll infants into interventional clinical trials as soon as possible after diagnosis, and ideally,
prior to the onset of significant denervation.
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Additional Supporting Information may be found in the
online version of this article:
Table S1. Enrolling NeuroNEXT sites. Enrolling NeuroNEXT clinical trial sites and NN101 site investigators and
staff.
Table S2. Pearson correlation coefficients between baseline motor function test score and putative SMA
biomarkers. Summary table of Pearson correlation coefficients. Shaded rows indicate a correlation with p value
that is equal to or less than 0.05.
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